Serum Institute

In view of rising cases of COVID-19 in various parts of the country, Union Health Minister Mansukh Mandaviya is learnt to have approved the inclusion of Serum Institute's Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday. Covovax is likely to be available on the portal in a few days at a price of Rs 225 per dose plus applicable GST. The move comes after a letter was written by Prakash Kumar Singh, Director, Serum Institute of India (SII) to the Union health ministry on March 27, the sources said. According to an official source, Singh had mentioned in his letter to the ministry that Covovax is a world class vaccine approved by the DCGI, WHO and USFDA and it should be included on the CoWIN portal as a heterologous booster dose for adults. Covovax can be administered to those who have already vaccinated with Covishield or Covaxin. Last month, the COVID-19 Working Group headed by Dr N K Arora had also recommended to the Health Mini

Amid rising coronavirus cases, the Serum Institute of India has written a letter to the Union health ministry seeking the inclusion of its COVID-19 vaccine Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday. The letter was written by Prakash Kumar Singh, Director, Serum Institute of India (SII) on March 27, they said. Last month, COVID-19 Working Group headed by Dr N K Arora had also recommended to the health ministry inclusion of Covovax on the CoWIN portal as a heterologous booster dose for adults who have been vaccinated with two doses of either Covishield or Covaxin. The Drugs Controller General of India (DCGI) had on January 16 approved the market authorisation for Covovax for those who have been administered two doses of either Covishield or Covaxin. Also, Covovax has been approved by the World Health Organisation (WHO) and the US Food and Drug Administration (USFDA). The DCGI had approved Covovax for restricted use in ...

Surge in demand for Covishield led to a huge spike in its revenues and profits

A day after the first indigenously developed Human Papillomavirus vaccine against cervical cancer was launched, Serum Institute of India CEO Adar Poonawalla on Wednesday said the vaccine will be available in small quantity this year and its production will be boosted next year to take care of the needs of the nation. Speaking on the sidelines of an event after presenting the vaccine to Union Health Minister Mansukh Mandaviya, Poonawalla said the vaccine 'CERVAVAC' will be made available through the government programme this year. The vaccine for 9-14-year-old was launched on Tuesday in the presence of Union Home Minister Amit Shah, Poonawalla, and Director of Government and Regulatory Affairs at Serum Institute of India, Prakash K Singh. It will be available at a much lower price than the internationally branded vaccines available in the market, Singh had said earlier. The vaccine will be included in the National Immunisation Programme by mid-2023, government officials had said.

'Suven alone has multiple engines of growth across all segments and a strong pipeline of Phase 3 and late Phase 2 molecules'

The Pune-based vaccine producer's value has increased 20 per cent to Rs 2.2 trillion in the past one year

India's drug regulator has allowed the export of the first produced-in-India vaccine against malaria, developed by scientists at the University of Oxford and manufactured by Serum Institute to the UK, official sources said on Thursday. The Drugs Controller General of India (DCGI) has granted permission to send two lakh doses of the vaccine. The move comes after an application was submitted by Prakash Kumar Singh, director, Government and Regulatory Affairs, at Serum Institute of India (SII) to DCGI on September 27 seeking permission to export the vaccine against malaria, official sources told PTI. "SII has developed the vaccine against malaria under leadership of our CEO Dr Adar C Poonawalla. We have been relentlessly working to make available made-in-India and world-class vaccines against malaria to our country and world at large," an official source quoted Singh as having said in the application. Currently, only one vaccine against malaria is available globally and GSK is the ...

It is classified as a sarbecovirus, a member of the Coronavirus family. It attaches to the same protein, ACE2 that Coronavirus uses to penetrate into human cells

Will be critical to the success of India's drive to eliminate TB by 2025

Serum India's product made in collaboration with state-run biotechnology department, expected to bring down prices

South Africa's Aspen Pharmacare has signed a deal with the Serum Institute of India to manufacture and sell four Aspen-branded vaccines for Africa

Among the companies that are working with ICMR are Serum Institute of India (SII), Reliance Life Sciences, Dr Reddy's Laboratories, and Biological E

The Pune-based company that manufactured the Covid-19 vaccine administered to most Indians is exploring more sophisticated delivery systems

What is keeping Adar Poonawalla busy these days?

Adar Poonawalla has taken Indian vaccines to the US and European markets. In an interview with Business Standard's Sohini Das, he tells about his plans for mass production of vaccines and more

In an interview, Arun Chandravarkar explains why a company must continue investing in R&D despite the impact on short-term Ebitda

"We are now getting to 'wet' pathology tests like blood tests etc and we have set up a centre which will have minimal human intervention and maximum automation

India started vaccinating adolescents (aged 15-18) from January, and further expanded the drive to include children as young as 12 years from March

The Competition Commission of India (CCI) has approved a proposed deal involving Serum Institute Life Sciences, Covidshield Technologies and Biocon Biologics. Once the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to the notice filed with the regulator. Covidshield Technologies Pvt Ltd (CTPL), a wholly-owned subsidiary of Serum Institute of Life Sciences, will be merged into Biocon Biologics. In a tweet on Wednesday, the watchdog said it has cleared the "merger by absorption of Covidshield Technologies into Biocon Biologics in consideration for acquisition of approximately 15 per cent equity shareholding of Biocon Biologics by Serum Institute Life Sciences." CTPL was incorporated to undertake the business of marketing, selling and distributing vaccines, drugs and other pharmaceutical products. Biocon Biologics Ltd is a subsidiary of Biocon Ltd. It offers treatment for chronic and acute diseases such as

Serum Institute of India on Friday said it has signed an agreement with the Symbiosis International University earlier this month to set up a research centre for vaccines and biologicals. The R&D (Research & Development) centre will lead the development of new vaccines, technologies, products and innovations in immunisation practices that provide equitable access to life-saving interventions, especially across Low- and Middle-Income Countries (LMICs). The entity will work towards improving health equity against future pandemics and infectious diseases. It will also ensure cross-programme coordination and collaboration, as the facility will be an ecosystem that would also have R&D centres for stem cells, nanotechnology, medical image analysis, applied artificial intelligence and waste resource management, among others. "The research centre will be instrumental in advancing indigenous capabilities for end-to-end development of any futuristic technology and projects in the ...

The decision, which the website attributes to Serum chief Adar Poonwala, comes a day ahead of the start of the programme to keep booster Covid-19 dose open for all adults